CSIMarket Company Name, Ticker, Industry, else..
 
Windtree Therapeutics Inc  (WINT)
 
Price: $0.0003 $0.00 0.000%
Day's High: $0.0003000000142492354 Week Perf: 200 %
Day's Low: $ 0.00 30 Day Perf: 50 %
Volume (M): 1,460 52 Wk High: $ 0.19
Volume (M$): $ 0 52 Wk Avg: $0.03
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 27
 Employees 15
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -41
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Windtree Therapeutics Inc. is a biotechnology company that focuses on developing novel therapeutics for respiratory diseases. The company is primarily known for its proprietary technology platform called KL4 surfactant, which is a synthetic formulation designed to mimic the natural surfactant found in healthy lungs. This platform is utilized in the development of various inhalation therapies for diseases such as respiratory distress syndrome (RDS) in premature infants and chronic obstructive pulmonary disease (COPD) in adults. The aim of Windtree Therapeutics is to improve the quality of life for patients suffering from respiratory conditions by providing effective and safe treatment options.


   Company Address: 2600 Kelly Road, Suite 100 Warrington 18976 PA
   Company Phone Number: 488-9300   Stock Exchange / Ticker: WINT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IOVA        9.74% 
NVAX        10.37% 
VXRT   -1.3%    
PULM   -7.95%    
SNGX      0% 
• View Complete Report
   



Shares

Windtree Therapeutics Regains Nasdaq Compliance After Strategic Reverse Stock Split

Published Mon, Mar 24 2025 12:00 PM UTC

Windtree Therapeutics Regains Compliance with Nasdaq Listing RulesWARRINGTON, Pa. In a significant turnaround for Windtree Therapeutics, Inc. (NasdaqCM: WINT), the biotechnology firm announced on March 24, 2025, that it has regained compliance with the Nasdaq listing rules following a challenging period. This reinstatement comes as a crucial step for the company, which has...
Shares

Windtrees Strategic Split: A Reverse Stock Split Aiming for Stability and Appeal,

Published Tue, Feb 18 2025 1:01 PM UTC

Reverse Stock Split Announced by Windtree Therapeutics: Analyzing the Strategic MoveIn a notable development for Windtree Therapeutics, Inc. (NasdaqCM: WINT), the company s board of directors has given the green light to a 1-for-50 reverse stock split. This strategic decision follows the approval from the company’s stockholders, who overwhelmingly supported the proposal du...
Clinical Study

Positive Phase 2b Results for Istaroxime in Acute Heart Failure with Early Cardiogenic Shock An Overview

Published Wed, Oct 9 2024 12:00 PM UTC

: Istaroxime, a novel therapeutic agent, has demonstrated promising efficacy in a Phase 2b study focusing on acute heart failure patients experiencing early cardiogenic shock. This article consolidates findings from recent announcements by Windtree Therapeutics and discusses the trial design and outcomes, emphasizing its potential impact in this critically ill patient popul...
Clinical Study

Istaroxime Showcases Promising Efficacy in Heart Failure Patients A Beacon of Hope in Early Cardiogenic Shock Manag...

Published Mon, Sep 30 2024 12:15 PM UTC

Heart failure, particularly in the context of early cardiogenic shock (ECS), represents a critical condition affecting millions globally. Traditional treatments have often struggled to effectively manage the complexities associated with this syndrome, where the heart s ability to pump blood is critically impaired. However, recent data emerging from Windtree Therapeutics indi...
Clinical Study

A Beacon of Hope Windtree Therapeutics Pioneers Advances in Cardiogenic Shock Management

Published Wed, Sep 25 2024 12:15 PM UTC

In the annals of medical advancement, one can scarcely overlook the titanic struggles and triumphs that bespeak the human endeavour to alleviate suffering. It is with a spirit of anticipation that we herald the promising news emerging from Windtree Therapeutics Inc. whose recent announcement lays forth the positive topline results gleaned from the Phase 2b SEISMiC Extension ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.05
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.01
Working Capital Ratio 0.33
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -8.77 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) -
Cash 0.01 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,732,933
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Windtree Therapeutics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.